Patents by Inventor Sejin Jeon

Sejin Jeon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION COMPRISING RILMENIDINE COMPOUND AS ACTIVE INGREDIENT FOR TREATMENT OF FRAGILE X SYNDROME OR RELATED DEVELOPMENTAL DISABILITY
    Publication number: 20230055339
    Abstract: The present invention relates to a composition for preventing, improving, or treating fragile X syndrome, fragile X syndrome-related developmental disorders, autism spectrum disorder or schizophrenia, comprising rilmenidine, a rilmenidine metabolite, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 5, 2021
    Publication date: February 23, 2023
    Applicant: NEUROVENTI
    Inventors: Sohyun JOO, Chanyoung SHIN, Sejin JEON, Taejin AHN
  • COMPOSITION COMPRISING LISURIDE COMPOUND FOR TREATING FRAGILE X SYNDROME OR RELATED DEVELOPMENTAL DISORDERS
    Publication number: 20230024384
    Abstract: The present invention relates to a composition for preventing, improving, or treating fragile X syndrome or related developmental disorders, comprising lisuride, a lisuride metabolite, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: January 26, 2023
    Applicant: NEUROVENTI
    Inventors: Sohyun JOO, Chanyoung SHIN, Sejin JEON, Taejin AHN
  • METHOD FOR TREATMENT OF AUTISM SPECTRUM DISORDER, MOUSE FOR MONITORING AUTISM SPECTRUM DISORDER, AND METHOD FOR SCREENING CANDIDATE MATERIAL FOR PREVENTION OR TREATMENT OF AUTISM SPECTRUM DISORDER
    Publication number: 20220047670
    Abstract: The present invention relates to a method for treating autism spectrum disorder, a mouse for monitoring autism spectrum disorder, and a method for screening a candidate for preventing or treating autism spectrum disorder. Specifically, according to the present invention, the output signal (or excitation of population) of neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum may be suppressed by introducing a halorhodopsin protein into neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum and then irradiating light to induce hyperpolarization of the halorhodopsin protein. Thus, the present invention has the effect of preventing or treating autism.
    Type: Application
    Filed: November 13, 2019
    Publication date: February 17, 2022
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jeongjin KIM, Hea-jin KIM, Yuliia STESHENKO, Sejin JEON, Hyunsoo PARK, Wooyeon SHIN
  • MARKER FOR DIAGNOSING ATHEROSCLEROSIS SEVERITY, AND DIAGNOSTIC METHOD USING SAME
    Publication number: 20220026443
    Abstract: The present invention pertains to: a marker composition for diagnosing atherosclerosis severity; a composition for diagnosing atherosclerosis severity; an atherosclerosis severity diagnosis kit including the composition; a method for screening substances for preventing or treating atherosclerosis; and a method for providing information about a diagnosis of atherosclerosis severity, wherein LGI3 expression or activity levels are used. According to the present invention, the severity of atherosclerosis can be diagnosed or predicted, and personalized medicine and predictive medicine can be practiced using such information. Moreover, the present invention can treat atherosclerosis without affecting other metabolic phenotypes by administering an LGI3 antagonist.
    Type: Application
    Filed: November 5, 2019
    Publication date: January 27, 2022
    Inventors: Goo Taeg Oh, Sejin Jeon, Tae Kyeong Kim, Yangsoo Jang, Sung-Jin Hong, Hye-Young Yun